A trial of SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma (The Scope Study)
Immune checkpoint inhibitors, which have revolutionized treatment in skin melanoma and other tumors, have less efficacy in UM with the best overall response rate (ORR) of 15.6%.
Uveal melanoma (UM) is a rare cancer in adults but its treatment is one of the clinical unmet needs in the melanoma field. Metastatic disease develops in approximately 50% of patients and is associated with poor survival due to the lack of effective treatment options. ...
The trial is designed to determine whether tebentafusp can improve overall survival in a heavily pretreated melanoma population that has limited approved options after progression on PD‑1 blockade.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research